99Z:F:F-MODUS THERAPEUTICS HLDG (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.131

Change

0.00 (0.00)%

Market Cap

USD 4.95M

Volume

1.00K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOV:F Novo Nordisk A/S

N/A

USD 526.04B
NOVA:F Novo Nordisk A/S

N/A

USD 524.27B
RGO:F Regeneron Pharmaceuticals Inc

N/A

USD 117.89B
CSJ:F CSL Limited

N/A

USD 88.37B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 87.08B
UNC0:F UCB S.A. UNSP.ADR 1/2

N/A

USD 30.35B
DUL:F Alnylam Pharmaceuticals Inc

N/A

USD 30.08B
1AE:F Argen-X

N/A

USD 29.18B
1AEA:F argenx SE

N/A

USD 29.18B
0QF:F Moderna Inc

N/A

USD 23.69B

ETFs Containing 99Z:F

DWMC 1.80 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.03% 52% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.03% 52% F 38% F
Trailing 12 Months  
Capital Gain -25.57% 46% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.57% 46% F 28% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -16.92% N/A N/A 13% F
Dividend Return -16.92% N/A N/A 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.86% N/A N/A 54% F
Risk Adjusted Return -70.92% N/A N/A 14% F
Market Capitalization 4.95M 11% F 8% B-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.